ClinicalTrials.Veeva

Menu

Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

S

Sheba Medical Center

Status

Unknown

Conditions

Retinopathy of Prematurity

Treatments

Drug: erythropoietin and early iron supplements

Study type

Observational

Funder types

Other

Identifiers

NCT00339001
SHEBA-06-4128-JK-CTIL

Details and patient eligibility

About

To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.

Sex

All

Ages

2 weeks to 3 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • all premature infants with birth weight of 1250 grams or less

Exclusion criteria

  • none

Trial contacts and locations

1

Loading...

Central trial contact

Jacob Kuint, MD; Irit Eisen, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems